Nirav H Shah1, Chuanhui Dong1, Mitchell S V Elkind1, Ralph L Sacco1, Armando J Mendez1, Barry I Hudson1, Shonni Silverberg1, Myles Wolf1, Tatjana Rundek1, Clinton B Wright2. 1. From the Evelyn F. McKnight Brain Institute (N.H.S., C.D., R.L.S., T.R., C.B.W.), Department of Neurology (N.H.S., C.D., R.L.S., T.R., C.B.W.), Department of Public Health Sciences (R.L.S., T.R., C.B.W.), Department of Human Genomics (R.L.S., T.R.), Department of Medicine (A.J.M.), The Neuroscience Program (R.L.S., C.B.W.), and Division of Endocrinology, Diabetes and Metabolism (B.I.H.), Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, FL; Center for Translational Metabolism and Health (M.W.), Institute for Public Health and Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (B.I.H., M.W.); and Department of Neurology (M.S.V.E.), Department of Medicine, College of Physicians and Surgeons (S.S.), and Department of Epidemiology, Mailman School of Public Health (M.S.V.E.), Columbia University, New York, NY. 2. From the Evelyn F. McKnight Brain Institute (N.H.S., C.D., R.L.S., T.R., C.B.W.), Department of Neurology (N.H.S., C.D., R.L.S., T.R., C.B.W.), Department of Public Health Sciences (R.L.S., T.R., C.B.W.), Department of Human Genomics (R.L.S., T.R.), Department of Medicine (A.J.M.), The Neuroscience Program (R.L.S., C.B.W.), and Division of Endocrinology, Diabetes and Metabolism (B.I.H.), Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, FL; Center for Translational Metabolism and Health (M.W.), Institute for Public Health and Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (B.I.H., M.W.); and Department of Neurology (M.S.V.E.), Department of Medicine, College of Physicians and Surgeons (S.S.), and Department of Epidemiology, Mailman School of Public Health (M.S.V.E.), Columbia University, New York, NY. c.wright21@med.miami.edu.
Abstract
OBJECTIVE: Elevated fibroblast growth factor 23 (FGF23), a hormone that regulates phosphate homeostasis, has been associated with mortality, cardiovascular events, and stroke, and to arterial calcification in chronic kidney disease, but its role in atherosclerosis is unclear and population-based studies are lacking. We hypothesized that elevated FGF23 would associate with carotid plaque presence, area, and echogenicity in the race/ethnically diverse community-based Northern Manhattan Study (NOMAS) sample. APPROACH AND RESULTS: There were 1512 stroke-free NOMAS participants with FGF23 and 2-dimensional carotid ultrasound data (mean age, 68±9 years; 61% women; 62% Hispanic, 18% black, and 18% white). We used multivariable linear and logistic regression to evaluate FGF23, continuously and by quintiles, as a correlate of carotid plaque, plaque area (cubic root transformed), and echogenicity adjusting for sociodemographic and vascular risk factors. Participants with FGF23 levels in the top quintile were more likely to have carotid plaque (odds ratio, 1.49; 95% confidence interval, 1.02-2.19; P=0.04) and larger plaque area (β=0.32 mm(2), 95% confidence interval, 0.10-0.53 mm(2); P=0.004) than those in the lowest quintile, adjusting for estimated glomerular filtration rate, demographics, and vascular risk factors. Linear regression models also showed that log transformed FGF23 (LnFGF23) associated with greater odds of plaque presence (odds ratio, 1.26 per LnFGF23; 95% confidence interval, 1.01-1.58; P=0.04), and plaque area (β=0.19 mm(2) per LnFGF23; 95% confidence interval, 0.07-0.31 mm(2); P=0.002). CONCLUSIONS: Higher FGF23 associated with greater likelihood and burden of carotid atherosclerosis independent of CKD. Atherosclerosis may be a mechanism through which FGF23 increases cardiovascular events and stroke.
OBJECTIVE: Elevated fibroblast growth factor 23 (FGF23), a hormone that regulates phosphate homeostasis, has been associated with mortality, cardiovascular events, and stroke, and to arterial calcification in chronic kidney disease, but its role in atherosclerosis is unclear and population-based studies are lacking. We hypothesized that elevated FGF23 would associate with carotid plaque presence, area, and echogenicity in the race/ethnically diverse community-based Northern Manhattan Study (NOMAS) sample. APPROACH AND RESULTS: There were 1512 stroke-free NOMASparticipants with FGF23 and 2-dimensional carotid ultrasound data (mean age, 68±9 years; 61% women; 62% Hispanic, 18% black, and 18% white). We used multivariable linear and logistic regression to evaluate FGF23, continuously and by quintiles, as a correlate of carotid plaque, plaque area (cubic root transformed), and echogenicity adjusting for sociodemographic and vascular risk factors. Participants with FGF23 levels in the top quintile were more likely to have carotid plaque (odds ratio, 1.49; 95% confidence interval, 1.02-2.19; P=0.04) and larger plaque area (β=0.32 mm(2), 95% confidence interval, 0.10-0.53 mm(2); P=0.004) than those in the lowest quintile, adjusting for estimated glomerular filtration rate, demographics, and vascular risk factors. Linear regression models also showed that log transformed FGF23 (LnFGF23) associated with greater odds of plaque presence (odds ratio, 1.26 per LnFGF23; 95% confidence interval, 1.01-1.58; P=0.04), and plaque area (β=0.19 mm(2) per LnFGF23; 95% confidence interval, 0.07-0.31 mm(2); P=0.002). CONCLUSIONS: Higher FGF23 associated with greater likelihood and burden of carotid atherosclerosis independent of CKD. Atherosclerosis may be a mechanism through which FGF23 increases cardiovascular events and stroke.
Authors: Jair Munoz Mendoza; Tamara Isakova; Ana C Ricardo; Huiliang Xie; Sankar D Navaneethan; Amanda H Anderson; Lydia A Bazzano; Dawei Xie; Matthias Kretzler; Lisa Nessel; L Lee Hamm; Lavinia Negrea; Mary B Leonard; Dominic Raj; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2012-05-03 Impact factor: 8.237
Authors: Frank Kuo; Hannah Gardener; Chuanhui Dong; Digna Cabral; David Della-Morte; Susan H Blanton; Mitchell S V Elkind; Ralph L Sacco; Tatjana Rundek Journal: Stroke Date: 2012-05-01 Impact factor: 7.914
Authors: Pranav S Garimella; Joachim H Ix; Ronit Katz; Michel B Chonchol; Bryan R Kestenbaum; Ian H de Boer; David S Siscovick; Shani Shastri; Jade S Hiramoto; Michael G Shlipak; Mark J Sarnak Journal: Atherosclerosis Date: 2014-01-04 Impact factor: 5.162
Authors: Sara Alsulaimani; Hannah Gardener; Mitchell S V Elkind; Ken Cheung; Ralph L Sacco; Tatjana Rundek Journal: Stroke Date: 2013-01-03 Impact factor: 7.914
Authors: Clinton B Wright; Chuanhui Dong; Matthew Stark; Shonni Silverberg; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco; Armando Mendez; Myles Wolf Journal: Neurology Date: 2014-04-04 Impact factor: 9.910
Authors: Bryan Kestenbaum; Michael C Sachs; Andy N Hoofnagle; David S Siscovick; Joachim H Ix; Cassianne Robinson-Cohen; Joao A C Lima; Joseph F Polak; Marc Blondon; John Ruzinski; Denise Rock; Ian H de Boer Journal: Circ Heart Fail Date: 2014-03-25 Impact factor: 8.790
Authors: Clinton B Wright; Nirav H Shah; Armando J Mendez; Janet T DeRosa; Mitsuhiro Yoshita; Mitchell S V Elkind; Ralph L Sacco; Charles DeCarli; Tatjana Rundek; Shonni Silverberg; Chuanhui Dong; Myles Wolf Journal: Stroke Date: 2016-03-08 Impact factor: 7.914
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Fang-Chi Hsu; Jianzhao Xu; S Carrie Smith; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Thomas C Register; Lijun Ma; J Jeffrey Carr; Barry I Freedman Journal: Diabetes Care Date: 2017-11-07 Impact factor: 19.112